CD36 and metabolic dysfunction-associated steatotic liver disease: In the early stages of MASLD, ceramides promote hepatic lipid uptake and storage via effects on free fatty acid transporters, such as CD36, and the disruption of protein kinase B (Akt) signaling, which inhibits glucose utilization [35,36].